Johnson & Johnson
J&J finally seals $30 billion deal for Actelion
January 26, 2017Sales and Marketing Actelion, Janssen, Johnson & Johnson
Johnson & Johnson has, as expected, wrapped up the deal to acquire Actelion in a deal worth $30 billion, working …
J&J to reveal drug price increases next month
January 16, 2017Sales and Marketing Johnson & Johnson
Next month, Johnson & Johnson will reveal the average price increases of its prescription drugs in a move to increase …
Actelion acquisition hokey-cokey continues with J&J returning to table
December 22, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Actelion, Johnson & Johnson, Sanofi
The Actelion takeover saga continues with Johnson & Johnson back in the game, and now re-entering into exclusive negotiations. Actelion …
J&J’s largest India site to finally operate by 2018
December 20, 2016Manufacturing and Production India, Johnson & Johnson
Johnson & Johnson has reportedly announced that its manufacturing plant in Telangana, India, its largest site in the country, is …
Sanofi eyes Actelion merger as J&J backs down
December 14, 2016Medical Communications, Research and Development, Sales and Marketing Actelion, Johnson & Johnson, Sanofi
After days of negotiations, Johnson and Johnson has stepped down from its attempts to acquire Swiss blood-pressure specialist Actelion, while …
J&J and Genmab’s drug races to second line treatment approval
November 22, 2016Manufacturing and Production, Research and Development, Sales and Marketing Genmab, Janssen, Johnson & Johnson, darzalex, multiple myeloma
Janssen, a part of Johnson & Johnson, and Genmab have announced that their multiple myeloma drug Darzalex (daratumumab) has been …
GSK/J&J release how their drug measures up against Humira
November 18, 2016Medical Communications, Research and Development GSK, Humira, Janssen, Johnson & Johnson, sirukumab
GlaxoSmithKline and Janssen, part of Johnson & Johnson, released the results of their two Phase III trials exploring treatment options …
Janssen’s Crohn’s treatment licensed for UK use
November 16, 2016Research and Development, Sales and Marketing Chrohn's disease, J&J, JJ, Janssen, Johnson & Johnson, Stelara
Janssen, a subsidiary of Johnson & Johnson, has announced that its treatment Stelara (ustekinumab) is now licensed by the European …
Collaboration on new therapeutic vaccine for HIV shows promise
November 10, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing HIV, J&J, JJ, Janssen, Johnson & Johnson
Janssen, part of Johnson & Johnson, released details on 9 November of the results of a new study looking into …
BenevolentAI announces licensing agreement with Janssen
November 8, 2016Research and Development Janssen, Johnson & Johnson, artificial intelligence
BenevolentAI, a British artificial intelligence company, announced a licensing agreement to develop a select number of drug candidates with Janssen, …
Pfizer sets release date for rival to J&J’s blockbuster drug
October 18, 2016Manufacturing and Production J&J, JJ, Johnson & Johnson, Pfizer, Remicade, inflectra
Pfizer have announced that they will begin shipping their rival to Johnson & Johnson’s Remicade by the end of November. …
AstraZeneca sells off third drug in five days
October 7, 2016Medical Communications AstraZeneca, Cilag GmbH, Johnson & Johnson, Rhinocort Aqua
AstraZeneca have completed a third sell off in the course of one week by divesting rights to Rhinocort Aqua outside …
Patients’ insulin pumps are revealed to be hackable by J&J
October 4, 2016Research and Development, Sales and Marketing FDA, Hackers, Johnson & Johnson, diabetes, insulin
Johnson & Johnson have begun warning patients that their insulin pumps, that patients attach to their bodies and are controlled …
J&J’s IL-23 drug guselkumab outstrips the competition in Phase III trial
October 3, 2016Research and Development, Sales and Marketing AbbVie, Humira, Johnson & Johnson, guselkumab
Johnson & Johnson’s IL-23 drug guselkumab proved to be more effective at clearing moderate to severe cases of the plaque …
Johnson & Johnson failed to inform FDA over faulty blood testing device in Phase III trial
September 29, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bayer, Johnson & Johnson, Xarelto, phase III, warfarin
The British Medical Journal, after its own investigation, found that Janssen knew early into the Phase III trial, known as …
Latest content
Five Facts about cardiovascular disease
